Private Placement Activity and M&A and Strategic Collaborations
Please complete the form below to download Oppenheimer's 1H 2024 Review for Biopharma, VC, M&A and BD Activity
After a beautiful July 4th weekend, we are happy to share Oppenheimer's Quarterly Private Placement Insights as well as our M&A and Strategic Collaborations Insights.
Spoiler Alert: The positive momentum from Q1 carried over into Q2 across the board.
Our reports focus on the more than robust private placement markets, active VC investors, private company valuations, insider vs. new investor participation, as well as steady M&A and BD activity for biopharma companies (see stats & details by clicking on the link above). Moreover, we have included additional thoughts on the BIOSECURE Act, FTC scrutiny, and the recent SCOTUS Chevron Doctrine decision, as well as an overview of FDA approvals in 1H24.
These reports are part of our leadership role in the biopharma industry. We hope to provide you with broader healthcare perspectives and actionable insights. Consider us a partner, trusted advisor, and extension of your team - with the Power of Oppenheimer Thinking.
This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2024 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 6761921.1